Education
About Us
Working with TipRanks
Follow Us
LFSC - ETF AI Analysis
Top Page
F/M Emerald Life Sciences Innovation ETF (LFSC)
Rating:55Neutral
Price Target:―
Positive Factors
Strong Recent Three-Month Performance
The ETF has shown solid gains over the last three months, suggesting recent momentum despite short-term pullbacks.
Several Strong-Performing Top Holdings
Key positions like Cogent Biosciences, Guardant Health, TransMedics Group, and Mirum Pharmaceuticals have delivered strong year-to-date performance, helping support the fund’s results.
Focused Exposure to U.S. Life Sciences
The fund is heavily invested in U.S. health care and life sciences companies, giving targeted exposure to a specialized innovation theme.
Negative Factors
Recent Short-Term Weakness
The ETF has experienced weak one-month and year-to-date performance, which may concern investors sensitive to near-term declines.
High Concentration in a Single Sector
With almost all assets in health care and life sciences, the fund is vulnerable to downturns or regulatory changes affecting that sector.
Mixed Performance Among Top Holdings
Several sizable positions, such as Wave Life Sciences and Travere Therapeutics, have lagged year-to-date, creating a drag on overall performance.
LFSC vs. SPDR S&P 500 ETF (SPY)
AUM95.00M
RegionNorth America
Expense Ratio0.54%
Beta1.11
IssuerF/m
Inception DateOct 30, 2024
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume13,235
30 Day Avg. Volume7,038
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
53.97Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering39
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
LFSC Summary
The F/M Emerald Life Sciences Innovation ETF (LFSC) is a fund that focuses on innovative health care companies, mainly in pharmaceuticals, biotechnology, and life sciences. It does not track a traditional index, but instead selects U.S.-based firms working on new drugs, medical treatments, and health technologies. Top holdings include companies like Guardant Health and TransMedics Group, which are involved in advanced diagnostics and organ transplant technologies. Investors might consider LFSC if they want growth potential from cutting-edge medical breakthroughs and added diversification within health care. However, this ETF is concentrated in a single, high-risk sector, so its price can be very volatile and may swing sharply up or down.
How much will it cost me?The F/M Emerald Life Sciences Innovation ETF (LFSC) has an expense ratio of 0.54%, meaning you’ll pay $5.40 per year for every $1,000 invested. This is slightly higher than average because it’s actively managed, focusing on specialized companies in the Pharma, Biotech & Life Sciences sector to capture unique growth opportunities.
What would affect this ETF?The LFSC ETF, focused on U.S.-based pharmaceutical, biotech, and life sciences companies, could benefit from advancements in medical technology, increased healthcare spending, and favorable regulatory approvals for new treatments. However, it may face challenges from rising interest rates, which can impact funding for innovation, and regulatory hurdles that could delay drug approvals or increase costs for its top holdings. Economic downturns or reduced government healthcare budgets could also negatively affect the sector.
LFSC Top 10 Holdings
LFSC is a pure play on U.S. life sciences, with almost everything riding on a handful of high‑beta biotech and medtech names. Mirum Pharmaceuticals and LivaNova have been doing the heavy lifting lately, with Mirum in particular powering ahead on upbeat clinical and earnings news. On the flip side, Cogent Biosciences and Guardant Health have been losing steam, acting as noticeable drags. Nektar and Spyre are more like wildcards—recently rising but still financially fragile—making this a focused, innovation‑driven fund where stock picking really matters.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Cogent Biosciences | 9.05% | $8.44M | $6.08B | 405.53% | 37 Underperform | |
| LivaNova | 7.00% | $6.52M | $3.54B | 61.79% | 63 Neutral | |
| TransMedics Group | 5.26% | $4.91M | $4.80B | 107.63% | 77 Outperform | |
| Mirum Pharmaceuticals | 4.78% | $4.46M | $5.30B | 102.30% | 56 Neutral | |
| Guardant Health | 4.42% | $4.12M | $12.14B | 131.94% | 61 Neutral | |
| Travere Therapeutics | 4.40% | $4.10M | $2.52B | 50.97% | 56 Neutral | |
| United Therapeutics | 4.35% | $4.05M | $21.26B | 57.65% | 79 Outperform | |
| Spyre Therapeutics | 4.32% | $4.02M | $3.19B | 98.00% | 43 Neutral | |
| Wave Life Sciences | 4.14% | $3.86M | $2.48B | 29.67% | 67 Neutral | |
| Nektar Therapeutics | 3.94% | $3.67M | $2.03B | 436.83% | 47 Neutral |
LFSC Technical Analysis
Negative
―
Price Trends
36.31
Negative
35.43
Negative
30.82
Positive
Market Momentum
-0.22
Positive
35.39
Neutral
16.39
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For LFSC, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 35.97, equal to the 50-day MA of 36.31, and equal to the 200-day MA of 30.82, indicating a neutral trend. The MACD of -0.22 indicates Positive momentum. The RSI at 35.39 is Neutral, neither overbought nor oversold. The STOCH value of 16.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFSC.
LFSC Peer Comparison
Comparison Results
Performance Comparison
LFSC
F/M Emerald Life Sciences Innovation ETF
34.52
12.60
57.48%
LFGY
YieldMax Crypto Industry & Tech Portfolio Option Income ETF
―
―
―
CEPI
REX Crypto Equity Premium Income ETF
―
―
―
GPTY
YieldMax AI & Tech Portfolio Option Income ETF
―
―
―
XPND
First Trust Expanded Technology ETF
―
―
―
SRHR
SRH REIT Covered Call ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents